A Phase Ⅱ Study of an All-Oral Combination of Low-dose Etoposide/Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and/or Taxanes
|ClinicalTrials.gov Identifier: NCT01589159|
Recruitment Status : Completed
First Posted : May 1, 2012
Last Update Posted : February 27, 2017
|Condition or disease||Intervention/treatment||Phase|
|Metastatic Breast Cancer||Drug: Capecitabine Drug: Etoposide||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||54 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase Ⅱ Study of an All-Oral Combination of Low-dose Etoposide/Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and/or Taxanes|
|Actual Study Start Date :||January 2013|
|Actual Primary Completion Date :||July 2016|
|Actual Study Completion Date :||December 2016|
Drug:capecitabine 700mg/m2, twice daily on days 1-14.
Etoposide 30mg/m2, once daily on days 1-7.
- Clinical benefit rate [ Time Frame: 24 weeks after the treatment ]Clinical benefit is defined as CR, PR, SD≥24 weeks.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01589159
|Peking University Cancer Hospital & Institute|
|Beijing, Beijing, China, 100142|
|Study Chair:||Yan Wei, Doctor||Peking University Cancer Hospital & Institute|